SIRT1 and Parkinson disease: For instance, differentiated PC12 cells, treated with 1-methyl-4-phenylpyridinium (MPP), show upregulation of miR-34a, miR-141, and miR-9, suggesting that perturbed expression of them may contribute to Parkinson’s disease (PD)-related pathogenic processes, probably by affecting the expression of B-cell lymphoma 2 (BCL2), BDNF, and SIRT1 as potential targets [63].